Vicore Pharma (Buy, TP: SEK90.00) - IPF data triggers a higher LOA
The Q4 report was a non-event, in our view. However, strong data released earlier this month from the interim analysis of the phase II AIR trial in IPF could be a game-changer for VP01 (despite the small patient sample). We believe the trial should be terminated and a phase III trial initiated on the back of the data. We have raised our LOA for VP01 in IPF from 15% to 25%. Following a change of analyst, we reiterate our BUY, with the higher LOA leading us to lift our target price to SEK90 (55).Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.